Tags

Type your tag names separated by a space and hit enter

Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects.
Brain Res Brain Res Rev 2003; 41(1):26-43BR

Abstract

There is good evidence that plant-derived and synthetic cannabinoids possess neuroprotective properties. These compounds, as a result of effects upon CB(1) cannabinoid receptors, reduce the release of glutamate, and in addition reduce the influx of calcium following NMDA receptor activation. The major obstacle to the therapeutic utilization of such compounds are their psychotropic effects, which are also brought about by actions on CB(1) receptors. However, synthesis of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, which also have neuroprotective properties, are increased under conditions of severe inflammation and ischemia, raising the possibility that compounds that prevent their metabolism may be of therapeutic utility without having the drawback of producing psychotropic effects. In this review, the evidence indicating neuroprotective actions of plant-derived, synthetic and endogenous cannabinoids is presented. In addition, the pharmacological properties of endogenous anandamide-related compounds that are not active upon cannabinoid receptors, but which are also produced during conditions of severe inflammation and ischemia and may contribute to a neuroprotective action are reviewed.

Authors+Show Affiliations

Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87, Umeå, Sweden. cf@pharm.umu.se

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12505646

Citation

Fowler, Christopher J.. "Plant-derived, Synthetic and Endogenous Cannabinoids as Neuroprotective Agents. Non-psychoactive Cannabinoids, 'entourage' Compounds and Inhibitors of N-acyl Ethanolamine Breakdown as Therapeutic Strategies to Avoid Pyschotropic Effects." Brain Research. Brain Research Reviews, vol. 41, no. 1, 2003, pp. 26-43.
Fowler CJ. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Brain Res Rev. 2003;41(1):26-43.
Fowler, C. J. (2003). Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Research. Brain Research Reviews, 41(1), pp. 26-43.
Fowler CJ. Plant-derived, Synthetic and Endogenous Cannabinoids as Neuroprotective Agents. Non-psychoactive Cannabinoids, 'entourage' Compounds and Inhibitors of N-acyl Ethanolamine Breakdown as Therapeutic Strategies to Avoid Pyschotropic Effects. Brain Res Brain Res Rev. 2003;41(1):26-43. PubMed PMID: 12505646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. A1 - Fowler,Christopher J, PY - 2002/12/31/pubmed PY - 2003/3/22/medline PY - 2002/12/31/entrez SP - 26 EP - 43 JF - Brain research. Brain research reviews JO - Brain Res. Brain Res. Rev. VL - 41 IS - 1 N2 - There is good evidence that plant-derived and synthetic cannabinoids possess neuroprotective properties. These compounds, as a result of effects upon CB(1) cannabinoid receptors, reduce the release of glutamate, and in addition reduce the influx of calcium following NMDA receptor activation. The major obstacle to the therapeutic utilization of such compounds are their psychotropic effects, which are also brought about by actions on CB(1) receptors. However, synthesis of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, which also have neuroprotective properties, are increased under conditions of severe inflammation and ischemia, raising the possibility that compounds that prevent their metabolism may be of therapeutic utility without having the drawback of producing psychotropic effects. In this review, the evidence indicating neuroprotective actions of plant-derived, synthetic and endogenous cannabinoids is presented. In addition, the pharmacological properties of endogenous anandamide-related compounds that are not active upon cannabinoid receptors, but which are also produced during conditions of severe inflammation and ischemia and may contribute to a neuroprotective action are reviewed. UR - https://www.unboundmedicine.com/medline/citation/12505646/Plant_derived_synthetic_and_endogenous_cannabinoids_as_neuroprotective_agents__Non_psychoactive_cannabinoids_'entourage'_compounds_and_inhibitors_of_N_acyl_ethanolamine_breakdown_as_therapeutic_strategies_to_avoid_pyschotropic_effects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165017302002187 DB - PRIME DP - Unbound Medicine ER -